PIK3CA and neoplasm: Reports indicate that resistance mechanisms may include genetic mutations, tumor microenvironment factors, and activation of alternative signaling pathways, such as secondary mutations in PIK3CA, PTEN loss or inactivation, and ESR1 mutations[13,14].